The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

And the company might one day follow Galapagos into decentralised manufacturing.

In first-line NSCLC the drug beats chemo, and not Keytruda.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.

The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.